<DOC>
	<DOCNO>NCT01748019</DOCNO>
	<brief_summary>ST1968 novel camptothecin derivative interacts topoisomerase I-DNA complex , induce S-Phase specific cytotoxicity . It endow potent antitumor activity increase Therapeutic Index respect clinically use analogue ( i.e.irinotecan topotecan ) xenograft model ( ovary , colon , head &amp; neck , cervix ) . Anti-tumor activity also note platinum resistant ovarian cell xenograft topoisomerase I mutant prostate cell line . The acceptable toxicity profile animal activity camptothecin-resistant cell line make ST1968 good candidate clinical trial .</brief_summary>
	<brief_title>ST1968 Intravenous ( Weekly ) Solid Tumors</brief_title>
	<detailed_description>Multicenter , open label , uncontrolled Phase I pharmacokinetic trial determine Maximum Tolerated Dose ( MTD ) ST1968 give intravenously ( I.V . ) every week 2 consecutive week every 3 week MTD ST1968 give I.V . every 3 week . A start dose 1.5mg/m2 give flat dose 2.5mg define , give Day 1 , Day 8 every 21 Days ( D1 , D8 Q21D schedule ) , 2 h. Starting dose Day 1 every 21 Days ( D1 Q21D schedule ) determine MTD D1 , D8 Q21D schedule . Plasma , urine pharmacokinetics patient ( minimum 3 pt cohort ) first cycle treatment least 6 patient Recommended Dose ( RD ) . During study hint anti-tumor activity also evaluate RECIST criterion .</detailed_description>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Namitecan</mesh_term>
	<criteria>Histological/cytological diagnosis solid tumor therapy proven efficacy exist . Preferably measurable disease ECOG performance status ≤ 1 . Age ≥ 18 year . Ongoing toxicity associate prior anticancer therapy ≤ grade 1 ( NCICTCAE V3.0 ) . Maximum 2 prior chemotherapy line advance disease ( include neoadjuvant adjuvant chemotherapy ) Adequate hematological , liver renal function Hemoglobin ≥ 9 g/dl ; ANC ≥ 1.5 x 109/L ; platelet ≥ 100 x 109/L ; Serum bilirubin ≤ upper normal limit ( UNL ) . ALT , AST ≤ UNL ≤ 2.5 x UNL case liver metastasis ; alkaline phosphatase ( liver isoenzyme fraction ) ≤ UNL ≤ 1.5xULN case liver metastasis ; albumin within normal limit ; Creatinine ≤1.5 mg/dl calculate creatinine clearance ≥ 60 ml/min . Life expectancy least 3 month Capacity understand nature trial give write informed consent . Less 4 week since last chemotherapy , radiotherapy prior investigational therapy . Less 2 week since last hormone immunotherapy signal transduction therapy . Active infection . Presence cirrhosis chronic hepatitis Presence serious cardiac ( congestive heart failure , angina pectoris , myocardial infarction within one year prior study entry , uncontrolled hypertension arrhythmia ) , neurological psychiatric disorder . Presence uncontrolled intercurrent illness condition judgement investigator would place subject undue risk interfere result study . Symptomatic brain metastasis ( include primary brain tumor ) leptomeningeal disease . Pregnancy lactation unwillingness use adequate method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ST1968</keyword>
	<keyword>Camptothecin</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Topoisomerase I</keyword>
</DOC>